A human liver microphysiology platform for investigating physiology, drug safety, and disease models

Experimental Biology and Medicine

Volumn 241, Issue 1, 2016, Pages 101-114

  Vernetti, Lawrence A ^a,b   Senutovitch, Nina ^a,b   Boltz, Robert ^a,b   DeBiasio, Richard ^a   Ying Shun, Tong ^a   Gough, Albert ^a,b   Taylor, D Lansing ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

hepatotoxicity; high content analysis; In vitro liver model; liver disease models; microfluidics; microphysiology systems

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; CAFFEINE; ETHOXYRESORUFIN; LACTATE DEHYDROGENASE; LEVOFLOXACIN; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; NIMESULIDE; TROGLITAZONE; TROVAFLOXACIN; TUMOR NECROSIS FACTOR ALPHA; UREA; PHARMACOLOGICAL BIOMARKER; PHOTOPROTEIN;

APOPTOSIS; ARTICLE; BILE FLOW; CONTROLLED STUDY; CRYOPRESERVATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LIVER CELL; LIVER FUNCTION; PROTEIN EXPRESSION; TOXICITY TESTING; UREA CYCLE; ARTIFICIAL LIVER; CELL SURVIVAL; DRUG EFFECTS; GENETIC PROCEDURES; LIVER; MICROFLUIDICS; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; TIME FACTOR;

BIOMARKERS, PHARMACOLOGICAL; BIOSENSING TECHNIQUES; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LIVER; LIVER, ARTIFICIAL; LUMINESCENT PROTEINS; MICROFLUIDICS; ORGAN CULTURE TECHNIQUES; TIME FACTORS;

EID: 84954229680     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370215592121     Document Type: Article

References (78)

1. P.GreavesA.WilliamsM.Eve. First dose of potential new medicines to humans: how animals help. Nat Rev Drug Dis2004; 3: 226–36.
2. D.KrewskiD.AcostaJr.M.AndersenH.AndersonJ.C.Bailar3rdK.BoekelheideR.BrentG.CharnleyV.G.CheungS.GreenJr.K.T.KelseyN.I.KerkvlietA.A.LiL.McCrayO.MeyerR.D.PattersonW.PennieR.A.ScalaG.M.SolomonM.StephensJ.YagerL.Zeise. Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environment Health Part B, Crit Rev2010; 13: 51–138.
3. V.Y.SoldatowE.L.LecluyseL.G.GriffithI.Rusyn. models for liver toxicity testing. Toxicol Res2013; 2: 23–39.
4. J.T.MayneW.W.KuS.P.Kennedy. Informed toxicity assessment in drug discovery: systems-based toxicology. Curr Opin Drug Discov Develop2006; 9: 75–83.
5. G.PatlewiczT.SimonK.GoyakR.D.PhillipsJ.C.RowlandsS.D.SeidelR.A.Becker. Use and validation of HT/HC assays to support 21st century toxicity evaluations. Regulator Toxicol Pharmacol2013; 65: 259–68.
6. S.MessnerI.AgarkovaW.MoritzJ.M.Kelm. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol2013; 87: 209–13.
7. R.KostadinovaF.BoessD.ApplegateL.SuterT.WeiserT.SingerB.NaughtonA.Roth. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol2013; 268: 1–16.
8. S.S.BaleL.VernettiN.SenutovitchR.JindalM.HegdeA.GoughW.J.McCartyA.BakanA.BhushanT.Y.ShunI.GolbergR.DeBiasioO.B.UstaD.L.TaylorM.L.Yarmush. In vitro platforms for evaluating liver toxicity. Experimental biology and medicine2014; 239: 1180–91.
9. K.A.GiulianoA.H.GoughD.L.TaylorL.A.VernettiP.A.Johnston. Early safety assessment using cellular systems biology yields insights into mechanisms of action. J Biomol Screen2010; 15: 783–97.
10. O.KeppL.GalluzziM.LipinskiJ.YuanG.Kroemer. Cell death assays for drug discovery. Nat Rev Drug Discov2011; 10: 221–37.
11. J.M.McKimJr. Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Combinat Chem High Throughput Screen2010; 13: 188–206.
12. L.VernettiW.IrwinK.A.GiulianoA.GoughK.JohnstonD.L.Taylor. Cellular systems biology applied to preclinical safety testing: a case study of CellCiphr™ profiling. Drug Efficacy, Safety Biol Discov: Emerg Technol Tool2009; 4: 53–53.
13. M.D.AleoY.LuoR.SwissP.D.BoninD.M.PotterY.Will. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology2014; 60: 1015–22.
14. Y.WillT.Schroeter. Deployment of in silico and in vitro safety assays in early-stage drug discovery. Future medicinal chemistry2012; 4: 1211–3.
15. N.GreeneM.D.AleoS.Louise-MayD.A.PriceY.Will. Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. Bioorganic Medicinal Chem Lett2010; 20: 5308–12.
16. Z.LinY.Will. Evaluation of drugs with specific organ toxicities in organ-specific cell lines. Toxicol Sci: Official J Soc Toxicol2012; 126: 114–27.
17. J.J.XuP.V.HenstockM.C.DunnA.R.SmithJ.R.ChabotD.de Graaf. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci: Official J Soc Toxicol2008; 105: 97–105.
18. S.N.BhatiaD.E.Ingber. Microfluidic organs-on-chips. Nat Biotechnol2014; 32: 760–72.
19. Annual thematic issue: the biology and medicine of microphysiological systems. In: J.P.Wikswo (ed). Experiment Biol Med2014; 239: 1061–271.
20. R.E.UngerV.Krump-KonvalinkovaK.PetersC.J.Kirkpatrick. In vitro expression of the endothelial phenotype: comparative study of primary isolated cells and cell lines, including the novel cell line HPMEC-ST1.6R. Microvasc Res2002; 64: 384–97.
21. C.H.JangJ.H.ChoiM.S.ByunD.M.Jue. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology2006; 45: 703–10.
22. L.XuA.Y.HuiE.AlbanisM.J.ArthurS.M.O'ByrneW.S.BlanerP.MukherjeeS.L.FriedmanF.J.Eng. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut2005; 54: 142–51.
23. J.C.Bonner. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev2004; 15: 255–73.
24. A.TourovskaiaM.FauverG.KramerS.SimonsonT.Neumann. Tissue-engineered microenvironment systems for modeling human vasculature. Experiment Biol Med2014; 239: 1264–71.
25. M.HegdeR.JindalA.BhushanS.S.BaleW.J.McCartyI.GolbergO.B.UstaM.L.Yarmush. Dynamic interplay of flow and collagen stabilizes primary hepatocytes culture in a microfluidic platform. Lab Chip2014; 14: 2033–9.
26. P.GodoyN.J.HewittU.AlbrechtM.E.AndersenN.AnsariS.BhattacharyaJ.G.BodeJ.BolleynC.BornerJ.BottgerA.BraeuningR.A.BudinskyB.BurkhardtN.R.CameronG.CamussiC.S.ChoY.J.ChoiJ.Craig RowlandsU.DahmenG.DammO.DirschM.T.DonatoJ.DongS.DooleyD.DrasdoR.EakinsK.S.FerreiraV.FonsatoJ.FraczekR.GebhardtA.GibsonM.GlanemannC.E.GoldringM.J.Gomez-LechonG.M.GroothuisL.GustavssonC.GuyotD.HallifaxS.HammadA.HaywardD.HaussingerC.HellerbrandP.HewittS.HoehmeH.G.HolzhutterJ.B.HoustonJ.HrachK.ItoH.JaeschkeV.KeitelJ.M.KelmB.Kevin ParkC.KordesG.A.Kullak-UblickE.L.LeCluyseP.LuJ.Luebke-WheelerA.LutzD.J.MaltmanM.Matz-SojaP.McMullenI.MerfortS.MessnerC.MeyerJ.MwinyiD.J.NaisbittA.K.NusslerP.OlingaF.PampaloniJ.PiL.PlutaS.A.PrzyborskiA.RamachandranV.RogiersC.RoweC.SchelcherK.SchmichM.SchwarzB.SinghE.H.StelzerB.StiegerR.StoberY.SugiyamaC.TettaW.E.ThaslerT.VanhaeckeM.VinkenT.S.WeissA.WideraC.G.WoodsJ.J.XuK.M.YarboroughJ.G.Hengstler. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archive Toxicol2013; 87: 1315–530.
27. S.R.KhetaniC.KanchagarO.UkairoS.KrzyzewskiA.MooreJ.ShiS.AoyamaM.AleoY.Will. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci: Official J Soc Toxicol2013; 132: 107–17.
28. J.HynesS.NadanacivaR.SwissC.CareyS.KirwanY.Will. A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. Toxicol in vitro: an international journal published in association with BIBRA2013; 27: 560–9.
29. S.NadanacivaM.D.AleoC.J.StrockD.B.StedmanH.WangY.Will. Toxicity assessments of nonsteroidal anti-inflammatory drugs in isolated mitochondria, rat hepatocytes, and zebrafish show good concordance across chemical classes. Toxicol Appl Pharmacol2013; 272: 272–80.
30. M.R.EbrahimkhaniJ.A.NeimanM.S.RaredonD.J.HughesL.G.Griffith. Bioreactor technologies to support liver function in vitro. Adv Drug Deliver Rev2014; 69–70: 132–57.
31. L.XiaS.NgR.HanX.TuoG.XiaoH.L.LeoT.ChengH.Yu. Laminar-flow immediate-overlay hepatocyte sandwich perfusion system for drug hepatotoxicity testing. Biomaterials2009; 30: 5927–36.
32. K.TaguchiM.MatsushitaM.TakahashiJ.Uchino. Development of a bioartificial liver with sandwiched-cultured hepatocytes between two collagen gel layers. Artificial Organ1996; 20: 178–85.
33. A.LangschS.GiriA.AcikgozI.JasmundB.FrericksA.Bader. Interspecies difference in liver-specific functions and biotransformation of testosterone of primary rat, porcine and human hepatocyte in an organotypical sandwich culture. Toxicol Lett2009; 188: 173–9.
34. U.YasarE.EliassonC.Forslund-BergengrenG.TybringM.GaddF.SjoqvistM.L.Dahl. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol2001; 57: 729–35.
35. M.H.GrantM.D.BurkeG.M.HawksworthS.J.DuthieJ.EngesetJ.C.Petrie. Human adult hepatocytes in primary monolayer culture. Maintenance of mixed function oxidase and conjugation pathways of drug metabolism. Biochem Pharmacol1987; 36: 2311–6.
36. M.L.CawoodH.P.FieldC.G.FordS.GillingwaterA.KicmanD.CowanJ.H.Barth. Testosterone measurement by isotope-dilution liquid chromatography-tandem mass spectrometry: validation of a method for routine clinical practice. Clin Chem2005; 51: 1472–9.
37. T.E.BapiroT.B.AnderssonC.OtterJ.A.HaslerC.M.Masimirembwa. Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol2002; 58: 537–42.
38. T.K.ChangD.J.Waxman. Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate. Meth Mol Biol2006; 320: 85–90.
39. J.D.WangN.J.DouvilleS.TakayamaM.ElSayed. Quantitative analysis of molecular absorption into PDMS microfluidic channels. Ann Biomed Eng2012; 40: 1862–73.
40. N.GrundP.MaierF.A.GiordanoJ.U.AppeltM.ZucknickL.LiF.WenzW.J.ZellerS.FruehaufH.AllgayerS.Laufs. Analysis of self-inactivating lentiviral vector integration sites and flanking gene expression in human peripheral blood progenitor cells after alkylator chemotherapy. Human Gene Ther2010; 21: 943–56.
41. W.KangW.A.MarascoH.I.TongM.ByronC.WuY.ShiS.SunY.SunY.Lu. Anti-tat hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages. J Neuroinflammat2014; 11: 195–195.
42. J.MatraiM.K.ChuahT.VandenDriessche. Recent advances in lentiviral vector development and applications. Mol Ther: J Am Soc Gene Ther2010; 18: 477–90.
43. M.CrispoM.VilarinoP.C.dos Santos-NetoR.Nunez-OliveraF.CuadroN.BarreraA.P.MuletT.H.NguyenI.AnegonA.Menchaca. Embryo development, fetal growth and postnatal phenotype of eGFP lambs generated by lentiviral transgenesis. Transgenic Res2015; 24: 31–41.
44. P.J.ShawM.J.HopfenspergerP.E.GaneyR.A.Roth. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci2007; 100: 259–66.
45. P.E.GaneyJ.P.LuyendykJ.F.MaddoxR.A.Roth. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chemico-Biol Interact2004; 150: 35–51.
46. K.S.LeeS.J.LeeH.J.ParkJ.P.ChungK.H.HanC.Y.ChonS.I.LeeY.M.Moon. Oxidative stress effect on the activation of hepatic stellate cells. Yonsei Med J2001; 42: 1–8.
47. K.WashingtonK.WrightY.ShyrE.B.HunterS.OlsonD.S.Raiford. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Human Pathol2000; 31: 822–8.
48. R.E.SchwartzK.TrehanL.AndrusT.P.SheahanA.PlossS.A.DuncanC.M.RiceS.N.Bhatia. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci USA2012; 109: 2544–8.
49. R.J.FontanaL.B.SeeffR.J.AndradeE.BjornssonC.P.DayJ.SerranoJ.H.Hoofnagle. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology2010; 52: 730–42.
50. G.OstapowiczR.J.FontanaF.V.SchiodtA.LarsonT.J.DavernS.H.HanT.M.McCashlandA.O.ShakilJ.E.HayL.HynanJ.S.CrippinA.T.BleiG.SamuelJ.ReischW.M.Lee. Group USALFS. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med2002; 137: 947–54.
51. R.J.Fontana. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology2014; 146: 914–28.
52. A.MathurP.LoskillS.HongJ.LeeS.G.MarcusL.DumontB.R.ConklinH.WillenbringL.P.LeeK.E.Healy. Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development. Stem Cell Res Ther2013; 4: S14–S14.
53. G.Vunjak-NovakovicS.BhatiaC.ChenK.Hirschi. HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease. Stem Cell Res Ther2013; 4: S8–S8.
54. A.BhushanN.SenutovitchS.S.BaleW.J.McCartyM.HegdeR.JindalI.GolbergO.B.UstaM.L.YarmushL.Vernetti. Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans. Stem Cell Res Ther2013; 4: 1–6.
55. A.M.ClarkS.E.WheelerD.P.TaylorV.C.PillaiC.L.YoungR.Prantil-BaunT.NguyenD.B.StolzJ.T.BorensteinD.A.LauffenburgerR.VenkataramananL.G.GriffithA.Wells. A microphysiological system model of therapy for liver micrometastases. Exp Biol Med (Maywood)2014.
56. R.JudsonK.HouckM.MartinT.KnudsenR.S.ThomasN.SipesI.ShahJ.WambaughK.Crofton. In vitro and modelling approaches to risk assessment from the U.S. Environmental Protection Agency ToxCast programme. Basic Clini Pharmacol Toxicol2014; 115: 69–76.
57. L.G.GriffithA.WellsD.B.Stolz. Engineering liver. Hepatology2014; 60: 1426–34.
58. T.MammotoA.MammotoD.E.Ingber. Mechanobiology and developmental control. Ann Rev Cell Develop Biol2013; 29: 27–61.
59. T.B.KnudsenD.A.KellerM.SanderE.W.CarneyN.G.DoerrerD.L.EatonS.C.FitzpatrickK.L.HastingsD.L.MendrickR.R.TiceP.B.WatkinsM.Whelan. FutureTox II: in vitro data and in silico models for predictive toxicology. Toxicol Sci: Official J Soc Toxicol2015; 143: 256–67.
60. D.H.AdamsC.JuS.K.RamaiahJ.UetrechtH.Jaeschke. Mechanisms of immune-mediated liver injury. Toxicol Sci: Official J Soc Toxicol2010; 115: 307–21.
61. C.Carter-KentN.N.ZeinA.E.Feldstein. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol2008; 103: 1036–42.
62. S.L.Friedman. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev2008; 88: 125–72.
63. S.CarottiS.MoriniS.G.CorradiniM.A.BurzaA.MolinaroG.CarpinoM.MerliA.De SantisA.O.MudaM.RossiA.F.AttiliE.Gaudio. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transplant: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2008; 14: 806–14.
64. G.CarpinoA.FranchittoS.MoriniS.G.CorradiniM.MerliE.Gaudio. Activated hepatic stellate cells in liver cirrhosis. A morphologic and morphometrical study. Italian J Anatomy Embryol = Archivio italiano di anatomia ed embriologia2004; 109: 225–38.
65. G.CarpinoS.MoriniS.Ginanni CorradiniA.FranchittoM.MerliM.SicilianoF.GentiliA.Onetti MudaP.BerlocoM.RossiA.F.AttiliE.Gaudio. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Digest Liver Disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver2005; 37: 349–56.
66. C.SalliotD.van der Heijde. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheumat Dis2009; 68: 1100–4.
67. N.KaplowitzL.D.DeLeve. Drug-induced liver disease, New York, USA: Academic Press, 2013.
68. K.TauraK.MiuraK.IwaisakoC.H.OsterreicherY.KodamaM.Penz-OsterreicherD.A.Brenner. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology2010; 51: 1027–36.
69. S.L.WenJ.H.GaoW.J.YangY.Y.LuH.TongZ.Y.HuangZ.X.LiuC.W.Tang. Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes. J Gastroenterol Hepatol2014; 29: 1932–42.
70. Senutovitch N, Vernetti L, Boltz R, DeBiasio R, Gough A, Taylor DL. Fluorescent protein biosensors applied to microphysiological systems. Exp Biol Med (Maywood) 2015;240:795–808
71. J.W.AllenS.R.KhetaniS.N.Bhatia. In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol Sci: Official J Society Toxicol2005; 84: 110–9.
72. J.P.WikswoE.L.CurtisZ.E.EagletonB.C.EvansA.KoleL.H.HofmeisterW.J.Matloff. Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip2013; 13: 3496–511.
73. R.IyengarS.ZhaoS.W.ChungD.E.MagerJ.M.Gallo. Merging systems biology with pharmacodynamics. Sci Translat Med2012; 4: 126ps7–126ps7.
74. S.SaseH.TakahashiR.ShigefukuH.IkedaM.KobayashiN.MatsumotoM.Suzuki. Measurement of blood flow and xenon solubility coefficient in the human liver by xenon-enhanced computed tomography. Med Phys2012; 39: 7553–9.
75. H.YamazakiT.Shimada. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Archive Biochem Biophys1997; 346: 161–9.
76. R.BortK.MaceA.BoobisM.J.Gomez-LechonA.PfeiferJ.Castell. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol1999; 58: 787–96.
77. W.TangR.A.StearnsR.W.WangS.H.ChiuT.A.Baillie. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol1999; 12: 192–9.
78. J.B.TangE.M.GoellnerX.H.WangR.N.TrivediStC.M.CroixE.JelezcovaD.SvilarA.R.BrownR.W.Sobol. Bioenergetic metabolites regulate base excision repair-dependent cell death in response to DNA damage. Mol Cancer Res: MCR2010; 8: 67–79.